Survival analysis revealed that patients with tumours expressing higher protein levels of EP300 demonstrated poorer overall survival, with a hazard ratio of 3.54, further supporting that EP300 may also play a role in facilitating the later stages of breast cancer progression (Supplementary Fig. 5e)45. Here, EP300 is linked to breast carcinoma.